Clozapine Tablets USP tablet, 100mg, 500-count bottle, Rx only, Distributed by: Aurobindo Pharma ...
FDA Drug Recall #D-1370-2020 — Class II — June 12, 2020
Recall Summary
| Recall Number | D-1370-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 12, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Aurobindo Pharma USA Inc. |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 1440 bottles |
Product Description
Clozapine Tablets USP tablet, 100mg, 500-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-846-05
Reason for Recall
Presence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.
Distribution Pattern
U.S.A. Nationwide
Lot / Code Information
Lot #: CZSC20003-A, Exp 1/2022
Other Recalls from Aurobindo Pharma USA Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0492-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 7.5 mg, a... | Apr 24, 2024 |
| D-0491-2024 | Class II | Clorazepate Dipotassium Tablets, USP, 3.75 mg, ... | Apr 24, 2024 |
| D-1171-2023 | Class II | Rasagiline Tablets 0.5mg, 30-count bottle, Rx o... | Aug 2, 2023 |
| D-1087-2023 | Class II | Rufinamide Tablets, USP 200 mg, packaged in 120... | Jul 21, 2023 |
| D-1088-2023 | Class II | Rufinamide Tablets, USP 400 mg, packaged in 120... | Jul 21, 2023 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.